









Markets
/
Stocks
/
nasdaq-flgt
/

Fulgent Genetics Inc

FLGT

23.440USD

-0.270-1.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

723.22MMarket Cap

LossP/E TTM



Fulgent Genetics Inc

23.440

-0.270-1.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fulgent Genetics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Fulgent Genetics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.67.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fulgent Genetics Inc's Score

Industry at a Glance

Industry Ranking

36 / 75

Overall Ranking

181 / 4521

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Fulgent Genetics Inc Highlights

StrengthsRisks

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Undervalued

The company’s latest PE is -16.78, at a low 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.23K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

33.667

Target Price

+41.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Fulgent Genetics Inc is 7.45, ranking 46 out of 75 in the Healthcare Providers & Services industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 84.07M, representing a year-over-year increase of 17.18%, while its net profit experienced a year-over-year increase of 54.89%.

Score

Industry at a Glance

Previous score

7.45

Change



Financials

8.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.16

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.76

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Fulgent Genetics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Fulgent Genetics Inc is 8.79, ranking 4 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -16.78, which is -145.37% below the recent high of 7.61 and -186.20% above the recent low of -48.02.

Score

Industry at a Glance

Previous score

8.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Fulgent Genetics Inc is 7.33, ranking 44 out of 75 in the Healthcare Providers & Services industry. The average price target is 35.00, with a high of 36.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

33.667

Target Price

+41.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Fulgent Genetics Inc

FLGT

CVS Health Corp

CVS

Teladoc Health Inc

TDOC

HCA Healthcare Inc

HCA

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Fulgent Genetics Inc is 6.43, ranking 59 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 27.22 and the support level at 21.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.37

Change

0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.855

Sell

RSI(14)

22.687

Sell

STOCH(KDJ)(9,3,3)

6.373

Oversold

ATR(14)

0.827

High Vlolatility

CCI(14)

-185.545

Sell

Williams %R

94.627

Oversold

TRIX(12,20)

-0.278

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

24.972

Sell

MA10

25.850

Sell

MA20

26.955

Sell

MA50

27.319

Sell

MA100

25.768

Sell

MA200

22.956

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Fulgent Genetics Inc is 5.00, ranking 49 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 59.35%, representing a quarter-over-quarter decrease of 0.77%. The largest institutional shareholder is The Vanguard, holding a total of 1.25M shares, representing 4.06% of shares outstanding, with 6.08% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Hsieh (Ming)

8.76M

-0.06%

BlackRock Institutional Trust Company, N.A.

1.99M

+22.91%

The Vanguard Group, Inc.

Star Investors

1.17M

+1.15%

Acadian Asset Management LLC

1.14M

+1.99%

Dimensional Fund Advisors, L.P.

1.13M

-0.12%

Millennium Management LLC

1.47M

+1.84%

Gao (Hanlin)

869.55K

-0.12%

BlackRock Financial Management, Inc.

661.24K

+135.39%

D. E. Shaw & Co., L.P.

567.77K

+19.16%

DWS Investments UK Limited

503.49K

+52.31%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fulgent Genetics Inc is 6.80, ranking 25 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Fulgent Genetics Inc’s latest ESG disclosure leads the Healthcare Providers & Services industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.